Yashili International Holdings Ltd Overview
Yashili was one of China's earliest domestic infant-formula brands. It was founded in Chaozhou, Guangdong, and listed in Hong Kong as a pure-play producer of infant milk formula (IMF) and nutrition foods. After Mengniu took control in 2013, Yashili became the vehicle for Mengniu's formula ambitions. Its multi-brand portfolio covered the Yashili-branded mass range, the premium Reeborne (瑞哺恩) line, the goat-milk range Doraler, the acquired Dumex (多美滋) China business, and distribution of Arla's Baby&Me and Milex brands. It also built a New Zealand manufacturing base at Pokeno. Despite these assets, the company lost ground through China's 2017 formula-registration regime, falling births, and premiumisation led by Feihe and the multinationals. It slipped from a top-seven national brand in 2006–2013 to outside the top ten by 2021. The company was privatised in 2023 as Mengniu and Danone unwound their partnership. Today Yashili is an operating unit inside Mengniu: Reeborne is its growth brand, the non-core assets (Dumex, the Arla distribution, Yashili NZ) have been divested, and the Guangdong and Shanxi plants remain.
Company's own description (latest listed filings). Yashili described itself as a domestically leading professional infant-formula producer with an international presence, focused on producing and selling premium infant formula and nutrition food (paraphrased from the 2022 transaction disclosures, as summarised by Zhong Lun, 2022). MarketScreener's profile summarises the company as an investment holding company that manufactures and sells dairy and food products, reported across five segments.
Business model. Yashili was a branded consumer-products manufacturer. Revenue was almost entirely product sales: no subscription or licensing revenue of note was disclosed. Distribution income came from selling third-party Arla brands between 2016 and 2022. Value was captured through:
-
Formula registration rights. Under China's SAMR formula-registration regime, each plant may hold a limited number of registered "series." Registrations are scarce, tradable assets; the Pokeno plant's two China-label registrations were the core of the 2025 sale to a2.
-
Brand premium, strongest in super-premium and organic tiers (Reeborne, Dumex, Arla Baby&Me Organic).
-
Channel reach across mother-and-baby (MBS) specialty stores, modern trade, and e-commerce. Arla noted that MBS stores were 69% and e-commerce 25% of China's early-life-nutrition market in 2021 (Arla press release, 2022).
Value-chain position. Yashili was a midstream processor and brand owner. It did not own dairy farms; it bought raw milk and imported base powders. In New Zealand, Yashili NZ ran a single site at Pokeno without its own farms (dairynews.today, 2025). This made gross margin sensitive to global whole-milk-powder and whey prices.
Customer types. Customers were distributors and MBS chains, e-commerce platforms (Tmall, JD), and supermarkets. End consumers are parents of infants aged 0–36 months, plus adults and seniors for adult milk powder and nutrition products.
End-markets. End-markets were the Chinese infant-formula market (the vast majority of revenue), adult and senior milk powder, rice cereal and nutrition supplements, and small export and Hong Kong sales.
Independent characterisation. Yashili had good assets but a weak strategic position. It had registered plants, an early mover's brand awareness in lower-tier cities, and Mengniu's channel support. It never solved its brand-positioning problem in the premium tier and suffered repeated management turnover. Industry analyst Song Liang attributed its decline to missing the 2017–2018 registration window and to unstable sales leadership without good incentive structures (Jiemian, 2022). Post-privatisation, Mengniu has concentrated the business on Reeborne. Mengniu's FY2025 results presentation credits Reeborne with launching China's first infant formula containing Sn-2 DHA & ARA and achieving robust growth.
Strategy
Last listed-era strategy (2020–2022 Annual Reports, paraphrased themes).
-
Brand focus on Reeborne as the national premium IMF brand, with a breast-milk-research narrative.
-
SKU rationalisation. Low-value, low-margin SKUs were cut, with management stating Q2 2020 revenue grew about 25% YoY after the restructuring (Jiemian, 2020).
-
Channel restructuring toward MBS and e-commerce, supported by Mengniu's distribution.
-
Portfolio simplification. The Arla distribution was exited in 2022–23 so Yashili could focus on its remaining portfolio (Arla press release).
Post-privatisation strategy (inside Mengniu).
Rationale: Privatisation was intended to let Mengniu restructure its formula assets, streamline operations and capture synergies (Jiemian English, 2023). Analysts noted it also removed connected-transaction and competition constraints, so Mengniu could integrate or acquire further formula brands (Jiemian, 2022).
Mengniu's "R&D-driven, brand-led" formula strategy (FY2025): The strategy centres on Reeborne innovations: Sn-2 DHA/ARA in 2025, then organic MLCT infant formula and breast-milk nutrition work in 2026. A second focus is precision nutrition for middle-aged and older consumers.
Asset monetisation: Yashili NZ was sold to a2 (2025), monetising the two China-label registrations at about NZ$275–282M.
Historical target: Mengniu's 2020 "create a new Mengniu in five years" plan targeted RMB 10bn of formula revenue within three years and over RMB 10bn by 2025 (Sina; Jiemian). Actual FY2022 formula revenue was RMB 3.86bn, so the target was missed by a wide margin.
Medium-term targets. No Yashili-specific targets are publicly disclosed. Mengniu has a 2025–2027 shareholder-return plan, but no formula-specific guidance beyond qualitative statements.
ESG commitments. Covered at Mengniu group level.
Products & Services
Pricing model. Retail premium pricing; specific price points are not publicly disclosed by the company. Two China-label IMF registrations were attached to the Pokeno plant (a2MC, 2025). The number of SAMR registered series held by the Guangdong and Shanxi plants is not publicly disclosed in sources reviewed.
Product Portfolio
| Brand / line | Segment | Description & positioning | Target customer | Launch / latest | Status (Oct 2026) |
|---|---|---|---|---|---|
Reeborne (瑞哺恩) | Milk powder | Premium-to-super-premium IMF positioned on breast-milk-like nutrition. July 2020 relaunch introduced the "亲乳" (close-to-breastmilk) series: 7 SKUs across mainstream cow-milk, organic and goat-milk formula, with a lighter taste and broader nutrient profile (Jiemian, 2020) | Urban and lower-tier parents, infants 0–36 months | Relaunched Jul 2020. 2025: first IMF with Sn-2 DHA & ARA. 2026: organic MLCT infant formula (Mengniu presentations) | Core growth brand within Mengniu |
Yashili (雅士利) | Milk powder | Legacy mass and mid-tier IMF and growing-up milk; China-label products historically also made at Pokeno | Value-conscious families, lower-tier cities | Brand since 1980s | Ongoing (scale not disclosed) |
Doraler (朵拉小羊) | Milk powder | Goat-milk infant formula sub-brand | Parents seeking goat-milk alternatives | Cited in 2021 portfolio (Jiemian, 2023) | Status not publicly disclosed |
Dumex (多美滋) | Milk powder | Former Danone multinational brand bought in 2015. Sales fell 68.3% to USD 64.6M in 2015 (CCM). Dumex China had post-tax profit of RMB 12M in 2021 vs RMB 40M in 2020 and net assets of −RMB 11M (Jiemian, 2022) | Premium segment | Acquired Dec 2015 | Divested to Danone in 2022–23 special deals |
Arla Baby&Me Organic / Baby&Me Blue Dawn / Milex | Distribution | Arla-owned imported formula, distributed by Yashili under agreement from 2016 | Organic and imported-formula buyers | 2016–2023 | Transferred to Arla (completed Sep 2023) |
Mengniu-branded adult / senior milk powder | Other milk powder | Adult, middle-aged and senior nutrition milk powders | Adults, seniors | Ongoing | Mengniu emphasises precision nutrition for middle-aged and older consumers (2026 interim) |
Nutrition / brewing products (冲调) | Nutrition | Rice cereal, drink powders and complementary nutrition foods | Infants (complementary feeding), families | Ongoing | FY2022 revenue RMB 195M |
a2 English-label formula (contract manufacture) | Others / NZ | Pokeno co-developed and produced a2 Gentle Gold and a2 Genesis for The a2 Milk Company | a2 (B2B) | Pre-2025 | Plant sold to a2 (Sep 2025) |
Financial Narrative
All figures in RMB million unless stated. IFRS.
Income statement
Sources: FY2022 Annual Results Announcement (29 Mar 2023) for FY2021–FY2022; PEdaily/TMTPost (2023) for FY2020 revenue and growth; Jiemian (2022) for FY2018–FY2020 net profit. FY2019 revenue is derived from FY2020 revenue and the disclosed +6.95% growth. FY2022 EBITDA was disclosed as a loss in the results announcement, but the figure was not captured; see the FY2022 Annual Report.
Per-share data (RMB cents)
FY2018–FY2020 EPS derived as net profit ÷ 4,745.56M shares. FY2021–FY2022 reported (FY2022 Results Announcement). No special dividend proposed for FY2021 or FY2022.
Margins
Derived: Revenue CAGR. FY2019–FY2022 ≈ +3.1% (3,412 → 3,738; derived). FY2014–FY2022 ≈ +0.6% (3,554 → 3,738). The longer view is effectively a decade of stagnation, against a FY2012 peak of RMB 3.65bn.
Interim snapshots
Sources: 2022 Interim Results Announcement; Jiemian (Aug 2020).
Balance sheet
Source: FY2022 Results Announcement. The group carried large net assets relative to market value; the HK$1.20 offer implied about 0.9x FY2022 book at contemporaneous FX. Finance income of RMB 31.7M in H1 2022 points to a meaningful net cash position, but the exact cash and debt balances are not captured here and should be confirmed in the FY2022 Annual Report.
Cash flow
Source: FY2022 Results Announcement (operating cash outflow worsened 87.4%).
Commentary
Trend. Yashili's financial history has three phases. The first is the boom to FY2012: revenue of RMB 3.65bn and net profit of RMB 470.5M. The second is collapse and impairment, FY2014–FY2017: revenue fell to RMB 2.2bn by FY2016, followed by losses of RMB 320M and RMB 180M. Mengniu wrote off about RMB 2.25bn of goodwill in 2016. The third is a thin-margin recovery, FY2018–FY2021. FY2021's 21.5% revenue jump to RMB 4.43bn was the best top-line year in the company's history. It nonetheless ended in a loss after a Dumex impairment of up to RMB 300M.
Inflection in 2022. FY2022 revenue fell 15.7%. Gross margin compressed by 4.8 percentage points to 28.1%, which management linked to the interim gross-margin decline. Operating cash flow deteriorated to −RMB 495M. A sub-scale player with high fixed sales and marketing costs saw negative operating leverage.
Drivers. The main drivers were demographic contraction, formula re-registration costs, raw-material inflation in 2021–22, impairment of acquired brands (Dumex), and structural MBS channel destocking.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment (CNY Mn) | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Milk powder products | — | 3,651 | 2,968 |
Other milk powder products (derived residual) | — | 438 | 512 |
Nutrition / brewing products (冲调) | — | 221 | 195 |
Others | — | 125 | 63 |
Total revenue | 3,649 | 4,434.7 | 3,738.2 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Metric (CNY Mn) | H1 2021 | H1 2022 |
|---|---|---|
Segment result – Segment 1 (milk powder) | 126.4 | -31.9 |
Segment result – Segment 2 | 4.4 | 1.8 |
Segment result – Segment 3 | 15.8 | 7.5 |
Segment result – Segment 4 | 6.5 | 1.1 |
Total segment results | 153.1 | -21.6 |
Group revenue | 2,156.9 | 1,886.7 |
Segment Overview
| Segment | FY2022 revenue (CNY Mn) | % of total | YoY |
|---|---|---|---|
Milk powder products | 2,968 | 79.4% | -18.7% |
Other milk powder products (derived) | 512 | 13.7% | positive (stated as growing) |
Nutrition / brewing products | 195 | 5.2% | -11.8% |
Others | 63 | 1.7% | -49.3% |
Total | 3738.2 | 100% | -15.7% |
Revenue by Segment (Half-Yearly)
| Metric (CNY Mn) | H1 2019 | H1 2020 |
|---|---|---|
Milk powder segment revenue | 1,398.7 | 1,290.1 |
Revenue by Segment (FY2018–FY2022)
| Metric (CNY Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Mengniu milk powder revenue (incl. Yashili, Bellamy's; FY2018–19 also incl. Junlebao-era effects) | 6,017 | 7,870 | 4,573 | 4,949 | 3,862 |
Revenue by Segment (H1 2025–H1 2026)
| Metric (CNY Mn) | H1 2025 | H1 2026 |
|---|---|---|
Mengniu Milk Formula revenue | 1,676 | 2,058 |
Income Statement
| Metric (CNY Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Revenue | — | 3,412 | 3,649 | 4,434.7 | 3,738.2 |
Gross profit | — | — | — | 1,460.0 | 1,050.3 |
Operating profit (loss) | — | — | — | -144.8 | -229.4 |
Pre-tax profit (loss) | — | — | — | -93.1 | -202.9 |
Net profit (loss) | 52 | 112 | 101 | -81.4 | -230.7 |
Total comprehensive income (loss) | — | — | — | -195.7 | -212.3 |
Per-Share Data
| Metric (MYR Bn cents) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Basic EPS | 1.1 | 2.4 | 2.1 | -1.7 | -4.9 |
Diluted EPS | — | — | — | -1.7 | -4.9 |
Dividend per share | — | — | — | 0 | 0 |
Net asset value per share (MYR Bn) | — | — | — | 1.2 | 1.1 |
Margin Analysis (%)
| Metric (%) | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Gross margin | — | — | 32.9 | 28.1 |
Operating margin | — | — | -3.3 | -6.1 |
Pre-tax margin | — | — | -2.1 | -5.4 |
Net margin | 3.3 | 2.8 | -1.8 | -6.2 |
Income Statement and Per-Share Data
| Metric (CNY Mn) | H1 2019 | H1 2020 | H1 2021 | H1 2022 |
|---|---|---|---|---|
Revenue | 1,747.4 | 1,644.9 | 2,156.9 | 1,886.7 |
Gross profit | — | — | 815.3 | 596.7 |
Pre-tax profit (loss) | — | — | 43.8 | -145.9 |
Attributable profit (loss) | 34.3 | 35.6 | — | — |
Basic EPS (MYR Bn cents) | — | — | 0.9 | -3.4 |
Finance income | — | — | 39.1 | 31.7 |
Liquidity & Coverage Ratios
| Metric (CNY Mn) | FY2021 | FY2022 |
|---|---|---|
Net assets (total equity) | 5,528.1 | 5,316.0 |
Net current assets (working capital) | 1,938.4 | 2,343.3 |
Cash Flow
| Metric (CNY Mn) | FY2021 | FY2022 |
|---|---|---|
Net operating cash flow | -264.4 | -495.4 |
Dividends paid | 0 | 0 |
Buybacks | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2021 | FY2022 |
|---|---|---|
ROE (net result ÷ year-end equity, %) | -1.5 | -4.3 |
Revenue by Region
| Region (revenue) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Yashili New Zealand Dairy revenue (NZD Mn) | 157.3 | 92.0 | 57.9 |
Yashili New Zealand Dairy net loss (NZD Mn) | — | 25.7 | 23.5 |
Region Overview
| Region | Split | Comment |
|---|---|---|
Mainland China | ≈95%+ (estimate based on business mix; not disclosed) | Core market; declining with births |
New Zealand (manufacturing / export) | Not disclosed at group level | Declining; sold Sept 2025 |
Capital Markets
| Item | Detail |
|---|---|
Listing status | Delisted ~5 July 2023; no trading |
Final exit price | HK$1.20 per share cash (scheme cancellation price) |
Implied equity value | ≈HK$5,695M (derived) |
Price to FY2022 book | ≈0.9x (HK$1.20 vs NAV RMB 1.1/share; FX-dependent, derived) |
1/3/5-year share price performance | Not applicable (no quotation after July 2023) |
Valuation multiples (P/E, EV/EBITDA) | Not meaningful: loss-making at exit |
Analyst consensus | None (no coverage) |
Dividend history | No dividends for FY2021 or FY2022; earlier history not captured |
Credit ratings | None (no rated debt); parent Mengniu ratings apply at group level |
Components
| Component (HKD Mn) | Value |
|---|---|
Scheme consideration to minorities | 1,370 |
Danone 25% stake purchase | 1,400 |
Aggregate cash outlay by Mengniu (privatisation + Danone shares) | 2,790 |
Analyst Conclusions
Management guidance. No Yashili-level guidance exists. Mengniu presents its formula business as R&D-driven and brand-led. It highlights Reeborne's product leadership, a 22.8% H1 2026 revenue rebound, and overseas expansion. Mengniu's group priorities are stabilising ambient liquid milk, growing cheese, fresh milk and formula, and delivering its 2025–2027 shareholder-return plan.
Bull case.
-
Growth has returned. Formula revenue grew 22.8% in H1 2026, with infant formula described as leading the industry. The rebound off a depressed 2023–2025 base, combined with Reeborne's innovation cadence, could restore the business toward its FY2021 peak of about RMB 4.4bn.
-
A cleaner portfolio. Dumex, the Arla distribution and the loss-making NZ plant are gone. The NZ unit alone had lost NZ$23.5–25.7M a year, so the remaining Guangdong and Shanxi operations should carry a better cost structure.
-
Group synergies without listed-company constraints. Mengniu's procurement, channels and lactoferrin and deep-processing capabilities can now be applied without connected-transaction friction.
Bear case.
-
Structural demand decline. Births have roughly halved since 2016, and Yili (18.1% share) and Feihe dominate. A sub-scale player faces permanent pricing pressure.
-
History of value destruction. More than RMB 2bn of Dumex losses, about RMB 2.25bn of goodwill impairment, and the miss on Mengniu's RMB 10bn formula target argue against a durable turnaround.
-
Divested assets now fund competitors. The ex-Yashili China-label registrations will relaunch under a2, and Arla is reinvesting in the brands Yashili once sold.
Catalysts and monitorables (next 12 months).
-
Mengniu FY2026 results (March 2027): full-year formula revenue and margin.
-
Reeborne market-share data from Nielsen or Kantar retail panels.
-
a2's SAMR approval for the relaunched ex-Pokeno registrations, a direct new competitor.
-
Effects of China's birth-support and childcare-subsidy policy on 2026–27 births.
-
Any Mengniu consolidation of formula entities (Yashili, Bellamy's) or further formula M&A.
-
Raw-milk price cycle and China Modern Dairy's financial health.
Analyst verdict. Yashili International Holdings no longer exists as an investable security. Mengniu completed a cash privatisation at HK$1.20 per share in July 2023, roughly 0.9x book, after a decade in which the company never recovered its FY2012 peak profitability. Any assessment today is really an assessment of a business unit inside China Mengniu Dairy and of Mengniu's formula strategy.
The listed-era record is poor. Revenue stagnated around RMB 3.4–4.4bn from FY2014 to FY2022, net margins never exceeded about 3% after FY2015, and the company ended its public life with a RMB 230.7M loss and a RMB 495M operating cash outflow. Its largest strategic bets failed or were reversed: Dumex was bought from Danone and sold back to it, Danone's equity alliance was unwound, the Arla distribution passed to Arla, and the Pokeno plant went to a2. Each exit simplified the business, but each also handed a competitor an asset.
What remains is more focused than it has been in years: two registered Chinese plants, a single hero brand (Reeborne) with a credible innovation pipeline, and an owner with national scale. The H1 2026 rebound in Mengniu's formula revenue (+22.8%) is the first clear evidence that the post-privatisation reset may be working. Some of that rebound reflects a low base and industry-wide stabilisation rather than share gains.
Our judgement is cautiously neutral. The business is now strategically rational, with low listed-company overhead and fewer distractions. It remains structurally sub-scale in a shrinking category dominated by Yili and Feihe. For investors, exposure exists only through Mengniu (2319.HK), where formula is under 5% of revenue and unlikely to drive group valuation. The key test over the next 12–18 months is whether Mengniu's formula line can sustain double-digit growth after the base effect fades.
Source list (primary and secondary documents referenced)
-
Yashili International Holdings Ltd — Annual Results Announcement FY2022 (HKEX, 29 Mar 2023); Interim Results H1 2022 (HKEX, 24 Aug 2022); Annual Report 2020 (HKEX, 20 Apr 2021); Annual Report 2012 (HKEX, 25 Apr 2013)
-
Joint Mengniu/Yashili announcements on privatisation (HKEX, 23 Jun, 30 Jun and 5 Jul 2023)
-
China Mengniu Dairy — 2025 Annual Results presentation and announcement; Annual Report 2025; 2026 interim presentation; press release 26 Mar 2026
-
The a2 Milk Company — FY25 results and Pokeno acquisition disclosures (via ChemLinked, Just Food, NutraFoods Spectrum, Inside FMCG, Food & Drink Business)
-
Arla Foods — press release on acquisition of China IMF business (2022)
-
Zhong Lun Law Firm (2022, 2023); Norton Rose Fulbright (May 2022)
-
MarketScreener / Zonebourse Yashili news registers
-
Jiemian (2020, 2022, 2023); PEdaily/TMTPost (2023); Sina Finance (2023); Beijing Business Today (2023); CCM (2016); just-food (2013); dairynews.today (2025); DairyReporter; Tiger Brokers / Deep News (2026); Dairy Business MEA (2025, 2026); Emperor Capital (Mar 2026)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Notes | Compensation |
|---|---|---|---|---|
Yan Zhiyuan (闫志远) | Executive President, Yashili International | From Jan 2020 (appointed 8 Jan 2020 per 2020 Annual Report; MarketScreener lists CEO age 43 from 08/01/2020) | Led the Reeborne relaunch (2020) | — |
(Name not captured) | CFO | From Dec 2020; appointed from Mengniu | Replaced the departing CFO | — |
Gao Fei (高飞) | CEO & Executive Director, China Mengniu Dairy (parent) | Current (FY2025 results) | Leads group formula strategy | See Mengniu Annual Report 2025 |
Chen Yiyi | Vice President, China Mengniu Dairy | Current | Spokesperson on overseas business, FY2025 | See Mengniu Annual Report 2025 |
“—” = not publicly disclosed.
Shareholding Trend
| Holder | Stake before Mar 2023 | Stake after Mar 2023 | Stake after Jul 2023 |
|---|---|---|---|
Mengniu International (Mengniu) | 2,422,117,713 shares (≈51.0%) | ≈51.0% | Combined 100% with offeror |
Danone Asia Baby Nutrition Pte Ltd | ≈25% | 0 (sold to Mengniu for ≈HK$1.4bn) | 0 |
Star Future Investment (Mengniu offeror) | — | ≈25% | Combined 100% |
Public / scheme shareholders | ≈24% (scheme shares ≈23.96%) | ≈23.96% | 0 (cancelled at HK$1.20) |
Competitive Landscape
Key Competitors
| Competitor | Type | Comparative revenue | Positioning vs. Yashili |
|---|---|---|---|
China Feihe | Domestic leader | RMB 18,592M (2020) | Dominant premium domestic brand; net profit RMB 7,437M (2020), about 70x Yashili's |
Yili (Pro-Kido 金领冠) | Domestic dairy major | Milk powder ranked No.1 in China in 2025; group revenue RMB 115.9bn (2025) | Leader; vertically integrated milk supply |
Junlebao | Domestic | RMB 14,468M (2020, total company) | Former Mengniu associate; mass-premium |
Ausnutria | Domestic (goat milk leader) | RMB 7,986M (2020) | Goat-milk leadership vs Doraler |
Biostime (H&H Group) | Domestic / premium | Not captured | Premium MBS channel |
Nestlé (Wyeth Illuma) | Multinational | Not captured | Super-premium leader |
Danone (Aptamil, Dumex) | Multinational | Not captured | Super-premium; now owns Dumex again |
a2 Milk Company | Foreign | NZ$1,902M group (FY2025); China-label IMF NZ$632.5M | Now owns ex-Yashili Pokeno registrations |
Beingmate | Domestic | Not captured | Similar mid-tier struggles |
Abbott, FrieslandCampina, Arla | Multinationals | Not captured | Arla took over the brands Yashili distributed |
Peer Comparison FY2024
| Metric | Yashili | Feihe | Junlebao | Ausnutria |
|---|---|---|---|---|
Revenue | 3,649 | 18,592 | 14,468 | 7,986 |
Net profit | 101 | 7,437 | 538 | 1,004 |
Net margin (%) | 2.8 | 40.0 | 3.7 | 12.6 |
Recent Developments
The register includes all identifiable entity-level events plus parent-level formula developments that directly concern the business.
After delisting, Yashili no longer issues HKEX announcements, and entity-level news (leadership changes, litigation, layoffs) is not publicly disclosed.*



